Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China
· Delayed Price · Currency is CNY 54.41
+2.18 (4.17%)
At close: May 13, 2025, 2:57 PM CST
SHA:688192 Revenue
Dizal (Jiangsu) Pharmaceutical had revenue of 159.64M CNY in the quarter ending March 31, 2025, with 96.32% growth. This brings the company's revenue in the last twelve months to 438.22M, up 153.88% year-over-year. In the year 2024, Dizal (Jiangsu) Pharmaceutical had annual revenue of 359.90M with 294.24% growth.
Revenue (ttm)
438.22M
Revenue Growth
+153.88%
P/S Ratio
57.04
Revenue / Employee
754.26K
Employees
581
Market Cap
25.00B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |